Search hospitals > North Carolina > Durham
Duke Eye Center
Claim this profileDurham, North Carolina 27701
Global Leader in Age-Related Macular Degeneration
Global Leader in Glaucoma
Conducts research for Macular Degeneration
Conducts research for Retinal Disease
Conducts research for Retinitis Pigmentosa
108 reported clinical trials
15 medical researchers
Summary
Duke Eye Center is a medical facility located in Durham, North Carolina. This center is recognized for care of Age-Related Macular Degeneration, Glaucoma, Macular Degeneration, Retinal Disease, Retinitis Pigmentosa and other specialties. Duke Eye Center is involved with conducting 108 clinical trials across 123 conditions. There are 15 research doctors associated with this hospital, such as Lejla Vajzovic, MD, Sharon F Freedman, MD, Cynthia A Toth, MD, and Ramiro Maldonado, MD.Area of expertise
1Age-Related Macular Degeneration
Global LeaderStage I
Stage II
CFI rare variant positive
2Glaucoma
Global LeaderTop PIs
Lejla Vajzovic, MDDuke Eye Center1 year of reported clinical research
Studies Retinitis Pigmentosa
Studies Retinal Disease
7 reported clinical trials
10 drugs studied
Sharon F Freedman, MDDuke University Eye Center3 years of reported clinical research
Studies Retinopathy of Prematurity
Studies Cystoid Macular Edema
5 reported clinical trials
7 drugs studied
Cynthia A Toth, MDDuke University Eye Center9 years of reported clinical research
Studies Retinopathy of Prematurity
Studies Cystoid Macular Edema
5 reported clinical trials
6 drugs studied
Ramiro Maldonado, MDDuke Eye Center1 year of reported clinical research
Studies Stargardt Disease
Studies Retinal Dystrophy
3 reported clinical trials
2 drugs studied
Clinical Trials running at Duke Eye Center
Age-Related Macular Degeneration
Retinal Disease
Macular Degeneration
Lazy Eye
Glaucoma
Stargardt Disease
Choroidal Neovascularization
Retinal Degeneration
None
Macular Pucker
RGX-314 Gene Therapy
for Age-Related Macular Degeneration
This trial is testing a new one-time gene therapy called RGX-314 for patients with wet AMD. The goal is to reduce the need for regular treatments by helping the eye produce its own protective proteins. This could make treatment easier and more effective for patients.
Recruiting2 awards Phase 32 criteria
4D-150 + EYLEA
for Age-Related Macular Degeneration
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration
Recruiting2 awards Phase 34 criteria
RGX-314 Gene Therapy
for Wet Age-Related Macular Degeneration
This trial is testing a new one-time gene therapy called RGX-314 for patients with wet AMD. It aims to help the eye make its own medicine to stop harmful blood vessels from causing vision loss. This could reduce the need for regular injections. RGX-314 modifies the retina's cells to create a treatment that may only be needed once.
Recruiting1 award Phase 2 & 36 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Duke Eye Center?
Duke Eye Center is a medical facility located in Durham, North Carolina. This center is recognized for care of Age-Related Macular Degeneration, Glaucoma, Macular Degeneration, Retinal Disease, Retinitis Pigmentosa and other specialties. Duke Eye Center is involved with conducting 108 clinical trials across 123 conditions. There are 15 research doctors associated with this hospital, such as Lejla Vajzovic, MD, Sharon F Freedman, MD, Cynthia A Toth, MD, and Ramiro Maldonado, MD.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.